August 22, 2019 / 5:07 PM / 3 months ago

BRIEF-Chugai Pharmaceutical Says Tecentriq Approved As Lung Cancer Treatment In Japan

Aug 22 (Reuters) - Chugai Pharmaceutical Co Ltd:

* CHUGAI PHARMACEUTICAL - TECENTRIQ RECEIVES APPROVAL FOR ADDITIONAL INDICATION OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER FROM JAPAN'S MHLW

* CHUGAI PHARMACEUTICAL CO LTD-BASED ON RESULTS FROM PHASE I/III IMPOWER133 STUDY, TECENTRIQ WITH CHEMOTHERAPY MET PRIMARY ENDPOINT OF OVERALL SURVIVAL Source text (bit.ly/2zhtTDX) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below